Biotechnology Industry Organization (BIO) welcomes advances in stem cell research, and stresses continued importance of pursuing all promising areas of research. – Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood issued the following statement regarding the news that researchers at the Harvard Stem Cell Institute created 20 disease-specific stem cell lines thru the new induced pluripotent stem cell (iPS) technique:
UT MD Anderson creates institute to accelerate cancer drug development — Organization focuses academic, private sector strengths on process in dire need of improvement – Academic and government leaders announced the establishment of a major new research institute at The University of Texas MD Anderson Cancer Center that will blend the best attributes of academic and industrial research to identify and validate new cancer targets, convert such scientific knowledge into new cancer drugs, and advance these novel agents into innovative clinical trials.
